EvolutionaryScale's breakthrough ESM3 model, powered by NVIDIA H100-enabled technology, is revolutionizing protein design for researchers. With investment from Lux Capital, NVIDIA, Amazon and others, EvolutionaryScale is pioneering programmable biology by enabling the discovery of proteins that target cancer cells, reduce plastic waste, and drive environmental solutions. The ESM3 model, trained on 2.8 billion protein sequences, offers significant advancements over previous versions by being natively generative and able to accept input for structure and function annotations. This technology accelerates protein discovery and offers a new frontier in in silico biological research. Generative AI capabilities of ESM-3, backed by NVIDIA BioNeMo, provide biologists with the tools to design novel proteins efficiently and creatively. The future of protein engineering and drug discovery lies in the innovative advancements made possible by EvolutionaryScale's groundbreaking technology.